AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $564 | -16.2% | 22,785 | -4.2% | 0.00% | 0.0% |
| Q2 2023 | $673 | -0.3% | 23,781 | -19.1% | 0.00% | 0.0% |
| Q1 2023 | $675 | -39.8% | 29,384 | -26.5% | 0.00% | -50.0% |
| Q4 2022 | $1,122 | -99.9% | 39,968 | +0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,130,000 | +27.8% | 39,962 | +0.2% | 0.00% | +100.0% |
| Q2 2022 | $884,000 | -24.1% | 39,881 | -0.3% | 0.00% | 0.0% |
| Q1 2022 | $1,164,000 | -15.1% | 39,999 | -4.1% | 0.00% | 0.0% |
| Q4 2021 | $1,371,000 | -39.8% | 41,699 | -15.5% | 0.00% | -50.0% |
| Q3 2021 | $2,278,000 | -27.3% | 49,366 | -13.1% | 0.00% | -33.3% |
| Q2 2021 | $3,132,000 | -13.5% | 56,838 | -18.9% | 0.00% | -25.0% |
| Q1 2021 | $3,620,000 | +5.0% | 70,104 | -11.9% | 0.00% | 0.0% |
| Q4 2020 | $3,449,000 | +8.8% | 79,604 | -12.1% | 0.00% | 0.0% |
| Q3 2020 | $3,171,000 | -40.2% | 90,604 | -8.6% | 0.00% | -42.9% |
| Q2 2020 | $5,300,000 | +36.3% | 99,104 | -9.6% | 0.01% | +16.7% |
| Q1 2020 | $3,889,000 | -10.9% | 109,604 | +19.9% | 0.01% | +20.0% |
| Q4 2019 | $4,364,000 | -20.1% | 91,400 | -45.8% | 0.01% | -28.6% |
| Q3 2019 | $5,464,000 | -36.1% | 168,649 | -1.6% | 0.01% | -36.4% |
| Q2 2019 | $8,552,000 | -4.8% | 171,449 | +28.8% | 0.01% | -8.3% |
| Q1 2019 | $8,980,000 | +66.5% | 133,155 | +13.8% | 0.01% | +50.0% |
| Q4 2018 | $5,395,000 | -31.0% | 117,005 | +15.4% | 0.01% | -11.1% |
| Q3 2018 | $7,820,000 | -7.7% | 101,400 | +0.8% | 0.01% | -18.2% |
| Q2 2018 | $8,474,000 | +0.9% | 100,600 | -2.0% | 0.01% | +10.0% |
| Q1 2018 | $8,399,000 | +56.3% | 102,700 | +9.3% | 0.01% | +66.7% |
| Q4 2017 | $5,374,000 | -14.4% | 94,000 | 0.0% | 0.01% | -25.0% |
| Q3 2017 | $6,275,000 | +25.0% | 94,000 | -3.7% | 0.01% | +14.3% |
| Q2 2017 | $5,021,000 | +17.5% | 97,590 | +33.3% | 0.01% | +16.7% |
| Q1 2017 | $4,274,000 | +49.0% | 73,191 | +6.5% | 0.01% | +50.0% |
| Q4 2016 | $2,868,000 | -24.9% | 68,720 | -5.0% | 0.00% | -33.3% |
| Q3 2016 | $3,820,000 | -2.4% | 72,323 | -22.6% | 0.01% | 0.0% |
| Q2 2016 | $3,914,000 | +11.5% | 93,435 | +8.1% | 0.01% | +20.0% |
| Q1 2016 | $3,509,000 | -37.5% | 86,435 | 0.0% | 0.01% | -44.4% |
| Q4 2015 | $5,611,000 | -8.0% | 86,435 | 0.0% | 0.01% | -10.0% |
| Q3 2015 | $6,101,000 | -27.3% | 86,435 | +14.5% | 0.01% | -16.7% |
| Q2 2015 | $8,388,000 | +227.8% | 75,469 | +178.1% | 0.01% | +200.0% |
| Q1 2015 | $2,559,000 | +88.7% | 27,135 | +124.1% | 0.00% | +100.0% |
| Q4 2014 | $1,356,000 | +26.8% | 12,106 | -30.5% | 0.00% | 0.0% |
| Q3 2014 | $1,069,000 | +34.0% | 17,424 | 0.0% | 0.00% | +100.0% |
| Q2 2014 | $798,000 | – | 17,424 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |